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The production of a standardized human anti-
lymphocyte globulin (ALG) has been hamper-
ed by the unavailability of a standard antigen 
for immunization, and by the finding that most 
immunization schedules produce variable re-
sults in different animals of a given species. In 
the present study it was found that horses 
immunized with cultured human lymphoblasts 
in a schedule of "maximum stimulation", all 
developed a very similar antibody response. 
Methods 
Preparation of ALG. Five horses were immun-
ized with cultured human lymphoblasts. At the 
first immunization 65 - 140 X 109 cells were 
injected subcutaneously in Freund's complete 
adjuvant (FCA) and at the same time 
20-50 X 109 cells were given intravenously. 
Subsequently, 2 to 5 intravenous booster doses 
of 25-100X 109 cells were given with 10-14 
86 
day intervals. In horse 5, three grams hydro-
cortisone was given with each of the booster 
injections. Five to 50 % of the injected cells 
were viable. 
Ten to 14 days after the last injection, the 
horses were bled to death. The horse serum was 
absorbed with human red cells, platelets and 
plasma, following which the globulin was pre-
cipitated with ammonium sulphate '. 
Testing of ALG. Lymphocytotoxic, leuko-
agglutinin, thromboagglutinin, and hemagglu-
tinin titers were performed with standard tech-
niques 2. Immunosuppressive effect in vivo was 
studied in the rhesus monkey skin graft model 
at the National Institute of Health. 
Pyrogen testing was carried out by lllJecting 
4 cc ALG intravenously into rabbits; endo-
toxin was assayed for according to Fritz and 
Nordenfelt 3. Antigenicity of the product was 
studied by following precipitin titers (Ouchter-
lony gel), in rabbits injected twice with 3 cc 
ALG. 
Results 
Characteristics of the ALG. The 5 horses under-
going immunization developed very similar 
antibody responses (Fig. 1). One horse died 
immediately after the first booster injection 
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Fig. 1 
Anti-white cell titers in 5 horses undergoing 3-pulse 
immunization with human cultured lymphoblasts. 
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Fig. 2 
Anti-white cell titers in a horse undergoing 6-pulse 
immunization. 
probably of anaphylaxis. After 3 injections, the 
other 4 horses all had developed cytotoxic 
titers of 1 : 8000. At the same time leukoagglu-
tinin titers were at least 1: 8000 in all the 
animals. Horse 3 was given three additional 
boosters at the end of which both anti-white 
cell titers had risen to 1 : 32,000 (Fig. 2). Horse 
5 is presently undergoing the same kind of 
extended immunization with the titers rising 
in a similar fashion. 
Table 1: 
In vitro characteristics of ALG prepared from the 
serum of 3 horses undergoing 3 or 6 pulse immuni-
zation with cultured human lymphoblasts. 
Horse 1 Horse 2 Horse 3 
3-pulse 3-pulse 6-pulse 
Lymphocytotoxic 
titer 4,000 4,000 32,000 
Leukoaggl utinin 
titer 8,000 8,000 16,000 
Thromboagglutinin 
titer 16 32 64 
Hemagglutinin 
titer 1,000 8,000 512 
Protein content 
(gOfo) 8.2 6.4 7.6 
The in vitro titers of the globulins prepared 
from the serum of horses 1- 3 are depicted in 
Table 1. The results of the tests for pyrogen-
icity, endotoxin effect and antigenicity are 
summarized in Table 2. 
Table 2: 
Toxicity of 2 batches of human ALG in the rabbit. 
Horse 1 Horse 3 
Test 3-pulse 6-pulse 
Pyrogenic response 0.60 C 1.2° C 
Endotoxin effect + 
Precipitin antibody titer 1 : 2 1: 4 
When given a total dose of 1 g/kg, the ALG 
prepared from serum of horse 3 prolonged skin 
graft survival in a monkey to 22-24 days 
(controls less than 12 days). 
Clinical trial. The ALG has been given to 26 
renal transplant recipients. Thirteen patients 
had living related, and 13 had cadaveric donors, 
respectively. Approximately 4 mg/kg/day was 
given intramuscularly for 8 days to 3 months; 
the dose was daily for 2 weeks and then less 
frequently. 
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When given alone prior to the combined im-
munosuppressive regimen with prednisone and 
azathioprine or cyclophosphamide, the ALG 
decreased the peripheral lymphocyte count in 
4 patients from an average of 2100 to 1300 
lymphocytes per mm3• In each of the same 
patients at least one positive delayed hyper-
sensitivity skin reaction for mumps, candida, 
streptokinase or vaccinia was decreased; to-
tally, 5 out of 7 such reactions were diminished. 
Pain and induration at the site of injection and 
moderate fever were common; significant 
thrombocytopenia and generalized skin reac-
tions were never seen. Two patients that re-
ceived ALG prepared from the serum of horse 
3, developed an anaphylactic reaction with 
therapy resistent circulatory collapse and pul-
monary edema leading to death. One of the 
patients had received ALG without the pro-
tection of simultaneously administered predni-
sone and azathioprine for the first 2 days. 
The other had the administration of ALG dis-
continued and then reinstituted 6 days later in 
connection with 2 consecutive transplantations. 
The anaphylactic reactions occurred after 2 and 
7 weeks of ALG administration, respectively. 
Sera from the 2 patients were studied simul-
taneously with sera from several other patients 
receiving ALG of the same batch and from 
other patients receiving other batches of ALG. 
In assaying precipitin and passive hemagglu-
tinin titers against horse protein, and passive 
cutaneous anaphylaxis in the guinea pig, no 
distinguishing features were found for the 
2 patients. 
With 1 to 9 months of follow-up there has 
been no patient loss further to the 2 cases 
undergoing anaphylactic reaction. One graft 
has been removed following an early urological 
complication. 
Discussion 
The cultured human lymphoblast offers the 
purest and best standardized antigen for the 
production of ALG 4 and has the additional 
advantage that it can be made available in 
large quantities. When given in an immuniza-
tion schedule characterized by the use of FCA 
with the initial subcutaneous injection, intra-
venous booster doses, and the use of large 
number of cells with each injection, a very 
similar antibody response was obtained in 
5 horses. The resulting ALG had high anti-
white cell titers in vitro, was immunosuppres-
sive in the monkey skin graft model and in-
duced peripheral lymphopenia and abolished 
delayed hypersensitivity skin reactions in 
patients. Side effects were moderate except in 
the 2 cases where anaphylactic shock led to the 
death of the patient. 
Several studies were performed trying to elu-
cidate the cause of these lethal complications 
which were the first to occur at our institution 
where ALG has been used for almost 6 years 
in more than 300 patients. The pertinent batch 
was pyrogenic and when retrospectively tested 
for endotoxin the material gave a positive 
result. In addition, it was more immunogenic 
in the rabbit than another batch tested. These 
findings might explain the untoward effects and 
underlines the importance of stringent in vitro 
toxicity control of ALG. 
Based on the experience with 5 horses we pro-
pose an immunization schedule as outlined in 
Table 3. The hydrocortisone is administered to 
prevent anaphylactic reactions in the horse. 
With this program the number of cells required 
for the immunization of one horse is 250-500 
Table 3: Proposed schedule for raising high titer ALG with cultured human lymphoblasts. 
Day 0 100 X 10' cells in FCA s. c. and 25 X 10' cells i. v. 
Days 14, 24, 34, 44, 54 25 -75 X 10· cells i. v. with 3 mg hydrocortisone 
Days 60-70 Bleeding of horse 
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X 10· and the procedure is completed in 2 
months. The expected yield of ammonium sul-
phate precipitated ALG will be approximately 
450 g from one horse. With the doses presently 
employed, that is a total of 10-20 mg globulin 
per patient, one horse can supply ALG for the 
treatment of 45 to 22 patients. 
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